Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM035
MIFTS: 47

Pulmonary Eosinophilia

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Eosinophilia

About this section

MalaCards integrated aliases for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 12 55 15 72
Asthmatic Pulmonary Eosinophilia 72

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9498
ICD9CM 35 518.3
MeSH 44 D011657
SNOMED-CT 68 91053000
ICD10 33 J82
UMLS 72 C0034068 C0340076
Sources

Summaries for Pulmonary Eosinophilia

About this section
Disease Ontology : 12 A hypereosinophilic syndrome characterized by the accumulation of eosinophils in the lungs.

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to chronic eosinophilic pneumonia and ascaris lumbricoides infection, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Prednisolone phosphate and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Pulmonary Eosinophilia

About this section

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 chronic eosinophilic pneumonia 33.0 RNASE3 IL5 CCL5 CCL11
2 ascaris lumbricoides infection 32.4 IL5 IL13
3 eosinophilic pneumonia 30.9 SFTPD RNASE3 IL5 IL13 CCL5 CCL17
4 filarial elephantiasis 30.7 IL5 IL4
5 cytokine deficiency 30.5 IL5 IL13
6 bronchitis 30.5 RNASE3 IL5 CCL11
7 churg-strauss syndrome 30.0 RNASE3 IL5 CCL17
8 respiratory syncytial virus infectious disease 29.8 IL5 IL13 CCL5
9 eosinophilic granuloma 29.6 RNASE3 EPX
10 idiopathic interstitial pneumonia 29.6 SFTPD IL4 IL13
11 aspergillosis 29.5 SFTPD IL5 IL4 CCL17
12 folliculitis 29.4 IL5 IL4 CCL5 CCL11
13 pneumonia 29.3 SFTPD IL5 IL13 CCL5 CCL11
14 interstitial lung disease 29.1 SFTPD IL4 CCL5 CCL17
15 hypereosinophilic syndrome 28.8 RNASE3 IL5 IL4 IL13 EPX CCL17
16 bronchiolitis 28.7 RNASE3 IL5 IL4 IL13 CCL5 CCL11
17 lung disease 28.7 SFTPD RNASE3 PDE4A IL5 IL13 CCL5
18 dermatitis 28.5 IL5 IL4 IL13 CCL17 CCL11
19 allergic bronchopulmonary aspergillosis 28.3 SFTPD IL5 IL4 EPX CCL17
20 allergic rhinitis 27.7 RNASE3 IL5 IL4 IL13 EPX CCL11
21 rhinitis 27.4 RNASE3 IL5 IL4 IL13 EPX CCL5
22 allergic asthma 27.0 RNASE3 IL5 IL4 IL13 EPX CCL5
23 allergic hypersensitivity disease 26.8 RNASE3 IL5 IL4 IL13 EPX CCL5
24 asthma 26.4 RNASE3 PDE4A IL5 IL4 IL13 EPX
25 loeffler syndrome 12.2
26 idiopathic eosinophilic pneumonia 10.9
27 idiopathic acute eosinophilic pneumonia 10.8
28 pemphigoid gestationis 10.5 IL5 CCL11
29 chronic meningitis 10.5 IL5 CCL11
30 loeffler endocarditis 10.5 RNASE3 IL5
31 papillary conjunctivitis 10.5 IL4 CCL11
32 cow milk allergy 10.5 RNASE3 IL5
33 vulvovaginitis 10.5 CCL5 CCL11
34 egg allergy 10.4 IL5 IL4
35 scleritis 10.4 IL5 IL4
36 maxillary sinusitis 10.4 RNASE3 CCL5
37 sulfamethoxazole allergy 10.4 IL5 IL4
38 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL5 IL13
39 trichinosis 10.4 IL5 IL4
40 gaucher disease, type ii 10.4 IL5 IL4
41 filariasis 10.4
42 non-suppurative otitis media 10.4 IL5 IL4
43 toxic oil syndrome 10.3 IL5 IL4
44 african tick-bite fever 10.3 IL13 CCL5
45 inclusion conjunctivitis 10.3 IL5 CCL5
46 wells syndrome 10.3 RNASE3 IL5
47 penicillin allergy 10.3 IL4 IL13
48 orofacial granulomatosis 10.3 IL4 CCL5
49 vasculogenic impotence 10.3 RNASE3 PDE4A
50 beta-lactam allergy 10.2 IL4 IL13

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Iron Deficiency Anemia Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to Pulmonary Eosinophilia
Sources

Symptoms & Phenotypes for Pulmonary Eosinophilia

About this section

UMLS symptoms related to Pulmonary Eosinophilia:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 CCL11 CCL17 CCL5 EPX IL13 IL4
2 immune system MP:0005387 9.61 CCL11 CCL17 CCL5 EPX IL13 IL4
3 respiratory system MP:0005388 9.02 CCL11 IL13 IL4 IL5 SFTPD
Sources

Drugs & Therapeutics for Pulmonary Eosinophilia

About this section

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
6
Nitric Oxide Approved Phase 4 10102-43-9 145068
7
Omalizumab Approved, Investigational Phase 4 242138-07-4
8 Benralizumab Approved, Investigational Phase 4 1044511-01-4
9
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
10 glucocorticoids Phase 4
11 Gastrointestinal Agents Phase 4
12 Neuroprotective Agents Phase 4
13 Hormones Phase 4
14 Methylprednisolone Acetate Phase 4
15 Antiemetics Phase 4
16 Anti-Inflammatory Agents Phase 4
17 Peripheral Nervous System Agents Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Hormone Antagonists Phase 4
20 Prednisolone acetate Phase 4
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
22 Autonomic Agents Phase 4
23 Anti-Allergic Agents Phase 4
24 Neurotransmitter Agents Phase 4
25 Albuterol Phase 4
26 Adrenergic Agonists Phase 4
27 Tocolytic Agents Phase 4
28 Adrenergic beta-2 Receptor Agonists Phase 4
29 Adrenergic beta-Agonists Phase 4
30 Adrenergic Agents Phase 4
31 Bronchodilator Agents Phase 4
32
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
33 Reslizumab Approved, Investigational Phase 3
34 Respiratory System Agents Phase 2, Phase 3
35 Anti-Asthmatic Agents Phase 2, Phase 3
36 Pharmaceutical Solutions Phase 3
37 Immunoglobulin G Phase 3
38 Antineoplastic Agents, Immunological Phase 2, Phase 3
39 Immunologic Factors Phase 3
40 Antibodies Phase 3
41 Immunoglobulins Phase 3
42 Antibodies, Monoclonal Phase 3
43
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924
44
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
45
Pramipexole Approved, Investigational Phase 2 104632-26-0 59868 119570
46 Indoleacetic Acids Phase 2
47 Sympathomimetics Phase 2
48
Salmeterol xinafoate Phase 2 94749-08-3 56801
49 Dermatologic Agents Phase 2
50 Fluticasone-Salmeterol Drug Combination Phase 2

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
2 Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
3 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
4 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
5 A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
6 A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
7 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
8 A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
9 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
10 A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810) Completed NCT02555371 Phase 3 Placebo
11 Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
12 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
13 A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma Not yet recruiting NCT04049175 Phase 3 Treatment A;Treatment B;Treatment C;Treatment D
14 An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
15 An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
16 A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
17 Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
18 The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial Completed NCT02560610 Phase 2 OC000459;Placebo
19 A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
20 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
21 A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma Recruiting NCT04046939 Phase 2 low-dose dexpramipexole;mid-dose dexpramipexole;high-dose dexpramipexole;placebo oral tablet
22 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia Unknown status NCT01152424
23 Serum Cytokine Profiles of Severe Asthma Completed NCT03563521
24 Characteristics of the Eosinophilic Asthma Phenotype: an Observational Study in Patients From a Tertiary Care Center With Various Asthma Severities: The Quebec Heart and Lung Institute-Laval University Retrospective Asthma Database Analysis Completed NCT03696914
25 Effet du Mepolizumab Sur la décroissance de la corticothérapie systémique Chez Des Patients Avec un Asthme éosinophilique sévère Etude Observationnelle, Suivi de Cohorte Via Une ATU Nominative Completed NCT03453021 Mepolizumab
26 A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma Recruiting NCT03739320 Mepolizumab 100 MG Injection [Nucala]
27 Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
28 A Multicentre, Single Arm, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Eosinophilic Asthma Patients Older Than 18 Starting Benralizumab in Switzerland Recruiting NCT03907137
29 Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease Recruiting NCT02852928
30 A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI Recruiting NCT03733535 Benralizumab;129 Xenon
31 Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients Recruiting NCT03976310 48 weeks of Benralizumab

Search NIH Clinical Center for Pulmonary Eosinophilia

Sources

Genetic Tests for Pulmonary Eosinophilia

About this section
Sources

Anatomical Context for Pulmonary Eosinophilia

About this section

MalaCards organs/tissues related to Pulmonary Eosinophilia:

41
Lung, T Cells, Testes, Heart, Bone, Bone Marrow, Neutrophil
Sources

Publications for Pulmonary Eosinophilia

About this section

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 771)
# Title Authors PMID Year
1
Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. 9 38
17996260 2008
2
Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. 9 38
17940489 2007
3
Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). 9 38
16120093 2005
4
Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. 9 38
16014847 2005
5
Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus. 9 38
15905537 2005
6
Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. 9 38
15158774 2004
7
Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. 9 38
12871220 2003
8
Elevated immunoglobulin E against recombinant Brugia malayi gamma-glutamyl transpeptidase in patients with bancroftian filariasis: association with tropical pulmonary eosinophilia or putative immunity. 9 38
12540554 2003
9
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. 9 38
11713356 2001
10
Glucocorticoid administration accelerates mortality of pneumovirus-infected mice. 9 38
11740726 2001
11
Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis. 9 38
11046102 2000
12
Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice. 9 38
10753501 2000
13
Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. 9 38
10590259 1999
14
Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. 9 38
10030835 1999
15
An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness. 9 38
9712797 1998
16
IgE down regulation and cytokine induction by Aspergillus antigens in human allergic bronchopulmonary aspergillosis. 9 38
9523846 1998
17
Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. 9 38
9802959 1998
18
Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. 9 38
9032176 1997
19
Cytokines as targets for the inhibition of eosinophilic inflammation. 9 38
9352584 1997
20
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. 9 38
8985399 1997
21
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. 9 38
8818342 1996
22
Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. 9 38
8784786 1996
23
Immunopurification and measurement of IgE in serum samples from bancroftian filariasis patients. 9 38
8627493 1996
24
Rapid and selective induction of blood eosinophilia in guinea pigs by recombinant human interleukin 5. 9 38
8664444 1995
25
Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. 9 38
7613159 1995
26
Animal models of occupational asthma. 9 38
8013613 1994
27
Allergic bronchopulmonary mycosis complicating cystic fibrosis. 9 38
1475542 1992
28
Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. 9 38
2010556 1991
29
Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels. 9 38
1899687 1991
30
The BALB/c mouse as a model for immunological studies of microfilariae-induced pulmonary eosinophilia. 9 38
2382764 1990
31
Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease. 38
31075351 2019
32
CD200R1 regulates eosinophilia during pulmonary fungal infection in mice. 38
31365119 2019
33
Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases. 38
29969926 2019
34
Diagnostic pitfalls of acute eosinophilic pneumonia in an adolescent boy following cigarette smoking: A case report. 38
31096462 2019
35
Cigarette smoking-induced acute eosinophilic pneumonia: A case report. 38
30817609 2019
36
Filarial tropical pulmonary eosinophilia. 38
30720371 2019
37
TNF-α-Producing Cryptococcus neoformans Exerts Protective Effects on Host Defenses in Murine Pulmonary Cryptococcosis. 38
31404168 2019
38
Extracorporeal Membrane Oxygenation in Severe Acute Eosinophilic Pneumonia. 38
31024915 2019
39
Elevated Periostin Concentrations in the Bronchoalveolar Lavage Fluid of Patients with Eosinophilic Pneumonia. 38
30612125 2019
40
[Vasculitides and eosinophilic pulmonary diseases]. 38
30367242 2018
41
Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation. 38
29428392 2018
42
BMS‑345541 inhibits airway inflammation and epithelial‑mesenchymal transition in airway remodeling of asthmatic mice. 38
30015827 2018
43
Anti-Inflammatory Activities of Pentaherbs formula and Its Influence on Gut Microbiota in Allergic Asthma. 38
30373169 2018
44
[Vasculitides and eosinophilic pulmonary diseases]. 38
30140942 2018
45
Inception of early-life allergen-induced airway hyperresponsiveness is reliant on IL-13+CD4+ T cells. 38
30194239 2018
46
Hypereosinophilic syndrome in the differential diagnosis of pulmonary infiltrates with eosinophilia. 38
29803709 2018
47
Tropical pulmonary eosinophilia masquerading as asthma in a 5-year-old girl. 38
28488945 2018
48
IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma. 38
29319845 2018
49
A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. 38
29779923 2018
50
Daptomycin-induced Acute Eosinophilic Pneumonia. 38
30397557 2018
Sources

Variations for Pulmonary Eosinophilia

About this section
Sources

Expression for Pulmonary Eosinophilia

About this section
Search GEO for disease gene expression data for Pulmonary Eosinophilia.
Sources

Pathways for Pulmonary Eosinophilia

About this section

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.76 RNASE3 IL5 IL4 IL13 EPX CCL5
2
PEDF Induced Signaling 64
Show member pathways
 13.42 IL5 IL4 IL13 CCL5 CCL17 CCL11
3
TGF-Beta Pathway 64
Show member pathways
 13.31 IL5 IL4 IL13 CCL5 CCL17 CCL11
4
Akt Signaling 64
Show member pathways
 13.19 IL5 IL4 IL13 CCL5 CCL17 CCL11
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.12 IL5 IL4 IL13 CCL5 CCL11
6
PAK Pathway 64
Show member pathways
 13.08 IL5 IL4 IL13 CCL5 CCL17 CCL11
7
Allograft rejection 37 1
Show member pathways
 12.67 RNASE3 IL5 IL4 IL13 EPX CCL11
8
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.17 IL5 IL4 IL13
9
IL-17 Family Signaling Pathways 65
Show member pathways
 12.13 IL5 IL4 IL13 CCL17 CCL11
10
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 12.09 CCL5 CCL17 CCL11
11
Bacterial infections in CF airways 22
Show member pathways
 11.99 SFTPD IL4 CCL11
12
Interleukin-4 and 13 signaling 66
11.81 IL4 IL13 CCL11
13
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.81 IL5 IL4 IL13 CCL5 CCL17 CCL11
14
Glucocorticoid receptor regulatory network 1
11.65 IL5 IL4 IL13
15
Innate Lymphoid Cell Differentiation Pathways 65
11.63 IL5 IL4 IL13
16
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.51 IL4 IL13 CCL5 CCL17 CCL11
17
IL4-mediated signaling events 1
11.47 IL5 IL4 CCL17 CCL11
18
Interleukin-10 signaling 66
11.39 IL4 IL13 CCL5
19
Development and heterogeneity of the ILC family 1
11.19 IL5 IL4 IL13
20
Lung fibrosis 1
11.15 IL5 IL4 IL13 CCL5 CCL11
21
Inflammatory Response Pathway 1
11.14 IL5 IL4
22
Cytokines and Inflammatory Response 1
11.13 IL5 IL4 IL13
23
OX40 Pathway 64
11.07 IL5 IL4 IL13
24
G-protein signaling_RhoB regulation pathway 22
10.86 IL5 IL4 IL13 CCL5 CCL17 CCL11
25
G-protein signaling_Rap2B regulation pathway 22
10.81 IL5 IL4 IL13 CCL5 CCL17 CCL11
26
Th2 Differentiation Pathway 65
10.68 IL5 IL4 IL13 CCL17 CCL11
Sources

GO Terms for Pulmonary Eosinophilia

About this section

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 SFTPD RNASE3 IL5 IL4 IL13 EPX
2 extracellular space GO:0005615 9.28 SFTPD RNASE3 IL5 IL4 IL13 EPX

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.77 SFTPD RNASE3 EPX
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.77 CCL5 CCL17 CCL11
3 chemotaxis GO:0006935 9.73 CCL5 CCL17 CCL11
4 cellular response to tumor necrosis factor GO:0071356 9.72 CCL5 CCL17 CCL11
5 cellular response to interferon-gamma GO:0071346 9.7 CCL5 CCL17 CCL11
6 neutrophil chemotaxis GO:0030593 9.69 CCL5 CCL17 CCL11
7 cellular response to interleukin-1 GO:0071347 9.67 CCL5 CCL17 CCL11
8 chemokine-mediated signaling pathway GO:0070098 9.63 CCL5 CCL17 CCL11
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IL4 IL13 CCL5
10 negative regulation of endothelial cell apoptotic process GO:2000352 9.58 IL4 IL13
11 positive regulation of JAK-STAT cascade GO:0046427 9.58 IL5 CCL5
12 eosinophil chemotaxis GO:0048245 9.57 CCL5 CCL11
13 inflammatory response GO:0006954 9.55 IL5 IL13 CCL5 CCL17 CCL11
14 macrophage chemotaxis GO:0048246 9.54 SFTPD CCL5
15 monocyte chemotaxis GO:0002548 9.54 CCL5 CCL17 CCL11
16 positive regulation of B cell proliferation GO:0030890 9.5 IL5 IL4 IL13
17 induction of bacterial agglutination GO:0043152 9.48 SFTPD RNASE3
18 lymphocyte chemotaxis GO:0048247 9.43 CCL5 CCL17 CCL11
19 negative regulation of complement-dependent cytotoxicity GO:1903660 9.4 IL4 IL13
20 cytokine-mediated signaling pathway GO:0019221 9.35 IL5 IL4 IL13 CCL5 CCL11
21 immune response GO:0006955 9.1 IL5 IL4 IL13 CCL5 CCL17 CCL11

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL5 CCL17 CCL11
2 lipopolysaccharide binding GO:0001530 9.37 SFTPD RNASE3
3 cytokine receptor binding GO:0005126 9.32 IL4 IL13
4 CCR4 chemokine receptor binding GO:0031729 9.16 CCL5 CCL17
5 CCR chemokine receptor binding GO:0048020 9.13 CCL5 CCL17 CCL11
6 cytokine activity GO:0005125 9.1 IL5 IL4 IL13 CCL5 CCL17 CCL11
Sources

Sources for Pulmonary Eosinophilia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....